Next big milestone

In 2023 Dicot started clinical trials. Read about the road ahead

Sexual dysfunctions

Erectile dysfunction affects 52% of all men over the age of 40.

The Dicot panel of experts

Dicot's panel of experts helps in profiling LIB-1 and preparing it for market acceptance.


The Pharmaceutical Project

Dicot is developing the candidate LIB-01 into a new modern potency drug for the world market. The ambition is to create a drug that has longer duration of action and fewer side effects than those available on the market today. This way, Dicot wants to drastically improve the treatment of erection problems and give affected men and couples a better intimate life. The goal is to make LIB-01 the first choice of treatment for erectile dysfunction and premature ejaculation.

Pharmacology studies

In a research collaboration with reputable Pelvipharm, the effect of the substance and future area of use will be clarified.

Read More >

Toxicology program

Toxicology determines the extent of a substance's possible side effects. Read more about Dicot's toxicology program here.

Read More >
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 867137.